<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Meningeal involvement with Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> cells constitutes the most challenging therapeutic problem in the management of <z:e sem="disease" ids="C0006413" disease_type="Neoplastic Process" abbrv="BL">Burkitt's tumour</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>The results of intrathecal chemotherapy with <z:chebi fb="0" ids="44185">methotrexate</z:chebi> or <z:chebi fb="1" ids="16040">cytosine</z:chebi> <z:chebi fb="0" ids="22601">arabinoside</z:chebi> in 55 episodes of malignant pleocytosis in 38 patients with <z:e sem="disease" ids="C0006413" disease_type="Neoplastic Process" abbrv="BL">Burkitt's tumour</z:e> are described </plain></SENT>
<SENT sid="2" pm="."><plain>The response was complete in nearly <z:hpo ids='HP_0000001'>all</z:hpo> patients after the administration of either agent </plain></SENT>
<SENT sid="3" pm="."><plain>Cerebrospinal fluid (C.S.F.) remissions were more prolonged in patients receiving intrathecal <z:chebi fb="0" ids="44185">methotrexate</z:chebi> or <z:chebi fb="1" ids="16040">cytosine</z:chebi> <z:chebi fb="0" ids="22601">arabinoside</z:chebi> daily for four days as opposed to a 10-day schedule </plain></SENT>
<SENT sid="4" pm="."><plain>A controlled randomized trial of "prophylactic" intrathecal chemotherapy in patients without malignant cells in the C.S.F. on admission showed no protective effect against the subsequent development of malignant pleocytosis </plain></SENT>
<SENT sid="5" pm="."><plain>Future therapeutic approaches are considered in the light of these results </plain></SENT>
</text></document>